Germany’s Merck KGaA and Britain’s GlaxoSmithKline on Thursday ended their collaboration on the cancer treatment bintrafusp alfa, once seen as one of Merck’s most promising experimental drugs.

The U.S. Food and Drug Administration rejected Sesen Bio’s lead candidate Viceneum (oportuzumab monatox-qqrs) as a treatment for BCG-unresponsive non-muscle invasive bladder cancer.

The U.S. drug regulator declined to approve Sesen Bio Inc.’s lead therapy candidate for a type of bladder cancer, the company said on Aug. 13, sending its shares down more than 80 percent.

The U.S. Food and Drug Administration’s Oncologic Drugs Advisory Committee did not agree in a meeting to maintain the accelerated approval of Bristol Myers Squibb’s Opdivo (nivolumab) as a second-line treatment of hepatocellular carcinoma.

AstraZeneca will voluntarily withdraw the use of the company’s Imfinzi to treat advanced bladder cancer in the United States after the cancer drug failed to meet post-approval requirements, the Anglo-Swedish drugmaker said.

Find out which biopharma companies are raking in the cash this week, as companies from around the globe provide updates on their financing rounds and IPOs.

The U.S. Food and Drug Administration granted expedited approval to UroGen Pharma’s Jelmyto (mitomycin) for pyelocaliceal solution for adults with low-grade upper tract urothelial cancer (LG UTUC) on the basis of data from the Phase III OLYMPUS trial.

AstraZeneca’s treatment options for Stage IV (metastatic) bladder cancer failed to hit the mark of improving overall survival in a Phase III trial.

Oncology is one of the most exciting areas in healthcare, as novel therapies continue to emerge that move forward our molecular understanding of the disease and offer effective treatment advances. This Q&A explores oncology innovation with Kantar’s Stephanie Hawthorne, Vice President of Oncology and Specialty Therapeutics.

The bladder cancer drug Padcev, which was approved by the U.S. Food and Drug Administration in December, secured Breakthrough Therapy designation for the treatment of patients with another type of bladder cancer.